5 Most Undervalued Pharma Stocks to Invest In

4. Grifols, S.A. (NASDAQ:GRFS)

PE Ratio: 11.24

Grifols, S.A. (NASDAQ:GRFS) is among the most undervalued stocks.

TheFly reported on May 12 that Deutsche Bank reduced its price target on GRFS from €11 to €10 while reaffirming a Hold rating on the stock.

Earlier on May 7, Grifols, S.A. (NASDAQ:GRFS) reported its results for the first quarter of 2026. The company recorded total revenue of €1.7 billion, reflecting a 3.3% increase on a constant currency basis compared with the prior year. Growth was primarily driven by its Biopharma segment, which advanced 6.8% in constant currency, supported by strong demand for immunoglobulin products. Performance was further aided by the rollout of Biotest’s next-generation IVIG Yimmugo in the U.S. and continued momentum from Gamunex in key U.S. and European markets. These gains were partly offset by weaker pricing in albumin in China and tougher comparisons in Alpha-1 and Specialty Proteins.

The corporation’s Adjusted EBITDA rose to €381 million, up 0.8% in constant currency, with a stable margin of 22.4%. Net profit reached €73 million, representing a 21.9% year-over-year increase. Free cash flow before M&A improved to negative €8 million, while leverage stood at 4.3x and liquidity totaled €1.573 billion, supported by recent refinancing actions that extended maturities and strengthened financial flexibility.

Grifols, S.A. (NASDAQ:GRFS) is a global healthcare company specializing in plasma-derived medicines. Founded in Barcelona in 1909, it provides biopharmaceutical products and medical services in over 110 countries.